Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

pembrolizumab 2MLN 8237 2pemigatinib 1liposomal doxorubicin 1cabiralizumab 1Nivolumab 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Advanced Malignancies × Clear all
NCT04837196 2025-08-08

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Astellas Pharma Inc

Phase 1/2 Completed
24 enrolled 47 charts

Advanced Malignancies

NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated
10 enrolled 9 charts

Advanced Malignancies

NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

AstraZeneca

Phase 1/2 Completed
30 enrolled 17 charts

Advanced Malignancies

NCT03158272 2020-12-21

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Bristol-Myers Squibb

Phase 1 Completed
19 enrolled 26 charts

Advanced Malignancies

NCT00651664 2019-03-15

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Takeda

Phase 1 Completed
59 enrolled 51 charts

Advanced Malignancies

NCT00500903 2019-03-14

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
87 enrolled 68 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡